With attention focused on the difficulties associated with traditional oncologic clinical trials, xCures’ Perpetual Trial and the potential for a Real World Data-based learning ecosystem has gained attention. Recently, Diagnostic World News interviewed xCures CEO Mika Newton about Perpetual Trials, AI, and the future of accelerating treatment and knowledge in the development of cancer treatments. To see more, go to Diagnostic World News.